1. Drugs in focus : budesonide and its role in paediatric gastrointestinal disordersSohail Aziz, Maria Giovanna Puoti, Amit Assa, Zrinjka Mišak, Emmanuel Mas, Osvaldo Borrelli, Jernej Dolinšek, Javier Martin-de-Carpi, Isabelle Scheers, Christos Tzivinikos, Matjaž Homan, Caterina Strisciuglio, 2026, pregledni znanstveni članek Ključne besede: adrenal suppression, corticosteroids
Objavljeno v DiRROS: 22.04.2026; Ogledov: 132; Prenosov: 129
 Celotno besedilo (1,44 MB)
Gradivo ima več datotek! Več... |
2. Approach to anaemia in gastrointestinal disease: a position paper by the ESPGHAN Gastroenterology CommitteeIlse Broekaert, Amit Assa, Osvaldo Borrelli, Marco Deganello Saccomani, Matjaž Homan, Javier Martin-de-Carpi, Emmanuel Mas, Erasmo Miele, Zrinjka Mišak, Sara Sila, Mike Thomson, Christos Tzivinikos, Jernej Dolinšek, 2025, pregledni znanstveni članek Objavljeno v DiRROS: 22.04.2026; Ogledov: 122; Prenosov: 132
Celotno besedilo (2,69 MB)
Gradivo ima več datotek! Več... |
3. Effectiveness and safety of Ustekinumab in pediatric ulcerative colitis : a multicenter retrospective study from the pediatric ibd porto group of ESPGHANShlomi Cohen, Helena Rolandsdotter, Kaija-Leena Kolho, Dan Turner, Christos Tzivinikos, Matteo Bramuzzo, Gemma Pujol-Muncunill, Darja Urlep Žužej, 2024, izvirni znanstveni članek Povzetek: Background and Objectives Current data on ustekinumab therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBDU) are limited. We aimed to evaluate the effectiveness and safety of ustekinumab in pediatric UC and IBDU. Methods This multicenter retrospective study included 16 centers affiliated with the IBD Interest and Porto groups of ESPGHAN. Children with UC or IBDU treated with ustekinumab were enrolled. Demographic, clinical, laboratory, endoscopic, and imaging data as well as adverse events were recorded. Analyses were all based on the intention-to-treat principle. Results Fifty-eight children (39 UC and 19 IBDU, median age 14.5 [IQR 11.5–16.5] years) were included. All had failed biologic therapies, and 38 (66%) had failed two or more biologics. Corticosteroid-free clinical remission (CFR) was observed in 27 (47%), 33 (57%), and 37 (64%) children at 16, 26, and 52 weeks, respectively. Normalization of C-reactive protein and calprotectin < 150 μg/g were achieved in 60% and 52%, respectively, by 52 weeks. Endoscopic and radiologic remissions were reached in 8% and 23%, respectively. The main predictors of CFR were diagnosis of UC compared with IBDU (hazard ratio [HR] 2.2, 95% CI 1.03–4.85; p = 0.041) and no prior vedolizumab therapy (HR 2.1, 95% CI 1.11–4.27; p = 0.023). Ustekinumab serum levels were not associated with disease activity. Adverse events were recorded in six (10%) children, leading to discontinuation of the drug in three. Conclusion Based on these findings, ustekinumab appears as an effective therapy for pediatric refractory UC and IBDU. The potential efficacy should be weighed against the risks of serious adverse events.
Ključne besede: Ustekinumab, pediatric ulcerative colitis, effectiveness
Objavljeno v DiRROS: 26.02.2026; Ogledov: 268; Prenosov: 138
Celotno besedilo (662,99 KB)
Gradivo ima več datotek! Več... |
4. Intestinal involvement in graft versus host disease in children : an overview by the ESPGHAN Gastroenterology CommitteeMarina Vincent, Amit Assa, Osvaldo Borrelli, Matjaž Homan, Javier Martin-de-Carpi, Zrinjka Mišak, Maria Giovanna Puoti, Isabelle Scheers, Sara Sila, Caterina Strisciuglio, Christos Tzivinikos, Jernej Dolinšek, Emmanuel Mas, 2025, pregledni znanstveni članek Povzetek: Graft versus host disease (GVHD) is a complication that frequently occurs afterhaematopoietic stem cell transplantation and concerns many children in paediatrichaematology‐oncology and bone marrow transplantation departments. It can affectvarious organs, with the skin, gastrointestinal tract and liver being the most com-monly involved. To confirm intestinal GVHD and to rule out differential diagnosesendoscopy is frequently needed. Currently, there are no specific consensus rec-ommendations concerning the best method for endoscopic exploration and medicalmanagement of this disease in children, with limited studies available, including alow number of patients. Sigmoidoscopy could be initially proposed under sedation. Ifsigmoidoscopy is normal or if a general anaesthesia is required, colonoscopy andupper endoscopy should be planned, avoiding duodenal biopsy because of the riskof duodenal haematoma. Regarding therapeutic options, corticosteroids are thefirst‐line treatment for GVHD. Ruxolitinib, a Janus kinase inhibitor, is indicated forchildren aged 12 years and older with acute or chronic GVHD who have aninadequate response to corticosteroids or other systemic therapies. Nutritionalsupport has a key role in the management of intestinal GVHD and should beconsidered to guarantee the best possible evolution of intestinal GVHD.
Ključne besede: GVHD, children, complication, endoscopy, haematopoietic stem cell transplantation, intestine
Objavljeno v DiRROS: 14.11.2025; Ogledov: 355; Prenosov: 235
Celotno besedilo (770,51 KB)
Gradivo ima več datotek! Več... |
